Bristol-Myers Squibb Research and Development CA209914

Renal Cell Carcinoma - Bristol-Myers Squibb Research and Development CA209914

Bristol-Myers Squibb Research and Development CA209914

Objective

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse "CheckMate 914: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 914"

Principal Investigator(s)
Hugo Hool, MD
Robert Figlin, MD

Clinical Trial Categories

  • Cedars-Sinai Clinical Trials